Bellerophon Therapeutics, Inc.
BLPH · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $16 | $13 | $18 | $11 |
| G&A Expenses | $6 | $7 | $8 | $6 |
| SG&A Expenses | $6 | $7 | $8 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$1 |
| Operating Expenses | $22 | $20 | $26 | $17 |
| Operating Income | -$22 | -$20 | -$26 | -$17 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | -$1 | $2 |
| Pre-Tax Income | -$22 | -$20 | -$27 | -$15 |
| Tax Expense | -$2 | -$2 | -$2 | -$2 |
| Net Income | -$20 | -$18 | -$25 | -$13 |
| % Margin | – | – | – | – |
| EPS | -2.08 | -1.87 | -3.17 | -2.95 |
| % Growth | -11.2% | 41% | -7.5% | – |
| EPS Diluted | -2.08 | -1.87 | -3.17 | -2.95 |
| Weighted Avg Shares Out | 10 | 10 | 8 | 5 |
| Weighted Avg Shares Out Dil | 10 | 10 | 8 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$22 | -$19 | -$27 | -$15 |
| % Margin | – | – | – | – |